Ascentage Corporate Presentation_Vfinal jpm.pdf

1、Dajun Yang,M.D.,Ph.D.Chairman&CEOJanuary 14,2026AAPG.NASDAQ|6855.HKEXCorporate Presentation44th AscentageJ.P.Morgan Healthcare ConferenceCautionary Note Regarding Forward-Looking Statements2This presentation has been prepared by Ascentage Pharma Group International(the“Company”)and includes forward-

2、looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended.All statements,other than statements of historical facts,contained in this presenta

3、tion may be forward-looking statements,including statements that express the Companys opinions,expectations,beliefs,plans,objectives,assumptions or projections regarding future events or future results of operations or financial condition.These forward-looking statements are subject to a number of r

4、isks and uncertainties that may cause actual results,levels of activity,performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.For factors that could cause actual results to differ materially from the forward-looking state

5、ments in this presentation,please see the sections titled“Risk factors”and“Special note regarding forward-looking statements and industry data”in the Companys Form 20-F filed with the SEC on April 16,2025,and other filings with the SEC that the Company made or makes from time to time,and with respec

6、t to non-U.S.investors only,the sections headed“Forward-looking Statements”and“Risk Factors”in the prospectus of the Company for its Hong Kong initial public offering dated October 16,2019 and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited that the Company made or makes fr